When was Avidence Therapeutics founded?

Avidence Therapeutics was founded in 2018.

Where is Avidence Therapeutics located?

Avidence Therapeutics is headquartered in Brooklyn, United States.

Who is the current CEO of Avidence Therapeutics?

Ang Li of Avidence Therapeutics. They have also founded 1 company.

Is Avidence Therapeutics a funded company?

Avidence Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Avidence Therapeutics rank among its competitors?

Avidence Therapeutics ranks 58th amongst 78 active competitors, of which 23 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Remedium Bio, which secured $1.5M in May, 2026.

Who are the top competitors of Avidence Therapeutics?

Avidence Therapeutics' top competitors include Eupraxia Pharmaceuticals, TissueGene and Immunis. Among them, Remedium Bio secured the most recent funding round in May, 2026.

Avidence Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Avidence Therapeutics is a funded company based in Brooklyn (United States), founded in 2018 by Ang Li. It operates as a Provider of regenerative medicine platform. The company has 78 active competitors, including 23 funded and 8 that have exited. Its top competitors include companies like Eupraxia Pharmaceuticals, TissueGene and Immunis.

Company Details

Avidence Therapeutics provides regenerative medicine platform. The company offers a platform aimed at modulating regenerative pathways through its cartilage regeneration platform, stem cell regeneration platform, and cellular microenvironment platform. The company's lead candidate is meant for osteoarthritis degenerative disc disease.

Website: avidenceinc.com
Email ID: *****@avidenceinc.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Brooklyn, United States

Stage

Funding Raised

Investors

Harlem Biospace

Ranked

58^th among 78 active competitors

Similar Companies

Eupraxia Pharmaceuticals & 81 more

View Avidence Therapeutics' full profile

Avidence Therapeutics is a funded company. Avidence Therapeutics has 1 institutional investor.

View details of Avidence Therapeutics's funding rounds and investors

The founders of Avidence Therapeutics is Ang Li. Ang Li is the CEO of Avidence Therapeutics.

Here are the details of Avidence Therapeutics' key team members:

Ang Li: Founder & CEO of Avidence Therapeutics.
Contact Info: 1 email address

View details of Avidence Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avidence Therapeutics include Eupraxia Pharmaceuticals, TissueGene and Immunis. Here is the list of Top 10 competitors of Avidence Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Eupraxia Pharmaceuticals 2012, Vancouver (Canada), Public	Sustained released formulation for osteoarthritis	$2.44M	SVB, National Research Council Canada & 2 others	62/100
2nd	TissueGene 1999, Rockville (United States), Series C	Developer of regenerative therapies for orthopedic diseases	$94.6M	Q Capital Partners, Maryland Stem Cell Research Fund ... Read more	55/100
3rd	Immunis 2018, Irvine (United States), Series A	Developer of cell therapies for age-related and disease-related immune deficits	$55.4M	Remiges Ventures, Bold Capital Partners & 4 others	55/100
4th	Levicept 2012, Sandwich (United Kingdom), Series B	Developer of therapeutics for the treatment of chronic pain	$50.9M	Pfizerpro, Gilde Healthcare & 8 others	55/100
5th	Remedium Bio 2020, Needham (United States), Series A	Developer of gene therapies for a broad range of diseases	$5M	LifeSpan Vision Ventures, Longevitytech.fund ... & 8 others	54/100
6th	Flexion Therapeutics 2007, Woburn (United States), Acquired	Developer of therapies for the treatment of musculoskeletal disorders	$62M	Versant Ventures, Novo Holdings & 5 others	53/100
7th	Cambium Bio 2007, Paddington (Australia), Public	Developer of therapeutics for ophthalmology and tissue regeneration	-	HHS, Zheng Yang Biomedical Technology & 1 others	49/100
8th	ZEO ScientifiX 2011, Fort Lauderdale (United States), Seed	Biopharmaceutical company focused on researching novel biological therapeutics	$1M	-	48/100
9th	4Moving Biotech 2020, Lille (France), Series B	Developer of therapeutics designed to translate scientific research into medicine	$31M	Bpifrance	48/100
10th	Genascence 2017, Palo Alto (United States), Series A	Developer of gene therapies for musculoskeletal and joint diseases	$10.5M	Polymerase Capital, DeepWork Capital & 1 others	47/100
58th	Avidence Therapeutics 2018, Brooklyn (United States), Funding Raised	Provider of regenerative medicine platform	-	Harlem Biospace	22/100